Clinical Trials · NCT01933022
A Study in Patients With Metastatic Prostate Cancer to Assess How the Drug Eligard®, Affects Certain Markers in Blood and Urine, Which Are Indicators for the Disease
- Phase
- Phase 4
- Recruitment status
- Terminated
- Sponsor
- Astellas Pharma Europe Ltd.
- Enrollment
- 1
- Start date
- Aug 2014
- Locations
- 3 sites, Netherlands
- Primary endpoint
- Changes from baseline of Testosterone levels in serum